Last reviewed · How we verify

Nicole Fram M.D. — Portfolio Competitive Intelligence Brief

Nicole Fram M.D. pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Prolensa 0.07% Ophthalmic Solution Prolensa 0.07% Ophthalmic Solution marketed Nonsteroidal anti-inflammatory drug (NSAID) Cyclooxygenase (COX-1 and COX-2) Ophthalmology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Actavis Inc. · 1 shared drug class
  2. Amneal Pharmaceuticals, LLC · 1 shared drug class
  3. Amzell · 1 shared drug class
  4. Assaf-Harofeh Medical Center · 1 shared drug class
  5. Azienda USL Reggio Emilia - IRCCS · 1 shared drug class
  6. Bausch & Lomb Incorporated · 1 shared drug class
  7. Bayer · 1 shared drug class
  8. Abbott · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Nicole Fram M.D.:

Cite this brief

Drug Landscape (2026). Nicole Fram M.D. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/nicole-fram-m-d. Accessed 2026-05-16.

Related